Login / Signup

Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study.

Naohisa YoshidaYoshiaki KuriuJun IkedaMichihiro KudouToshihiko KirishimaTetsuya OkayamaKoji MiyagawaTsuyoshi TakagiMasayoshi NakanishiToshifumi DoiTakeshi IshikawaYoshito ItohEigo Otsuji
Published in: International journal of clinical oncology (2023)
A better OS and PFS comparing TAS-102 + Bev to TAS-102 for CRC was achieved in a large number of real-world patients.
Keyphrases
  • metastatic colorectal cancer
  • risk factors
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease